---
title: 'A multi-center interventional study to assess pharmacokinetics, effectiveness,
  and tolerability of prolonged-release tacrolimus after pediatric kidney transplantation:
  study protocol for a prospective, open-label, randomized, two-phase, two-sequence,
  single dose, crossover, phase III b trial'
date: '2024-03-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38444519/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240306170534&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Tacrolimus, a calcineurin inhibitor (CNI), is currently
  the first-line immunosuppressive agent in kidney transplantation. The therapeutic
  index of tacrolimus is narrow due to due to the substantial impact of minor variations
  in drug concentration or exposure on clinical outcomes (i.e., nephrotoxicity), and
  it has a highly variable intra- and inter-individual bioavailability. Non-adherence
  to immunosuppressants is associated with rejection after kidney transplantation,
  which is ...'
disable_comments: true
---
BACKGROUND: Tacrolimus, a calcineurin inhibitor (CNI), is currently the first-line immunosuppressive agent in kidney transplantation. The therapeutic index of tacrolimus is narrow due to due to the substantial impact of minor variations in drug concentration or exposure on clinical outcomes (i.e., nephrotoxicity), and it has a highly variable intra- and inter-individual bioavailability. Non-adherence to immunosuppressants is associated with rejection after kidney transplantation, which is ...